

Melissa A Reimers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4869507/publications.pdf>

Version: 2024-02-01

20
papers

723
citations

840776

11
h-index

888059

17
g-index

21
all docs

21
docs citations

21
times ranked

1493
citing authors

#	ARTICLE	IF	CITATIONS
1	Association Between Local Radiation Therapy to the Primary Bladder Tumor and Overall Survival for Patients with Metastatic Urothelial Cancer Receiving Systemic Chemotherapy. <i>European Urology Oncology</i> , 2022, 5, 246-250.	5.4	5
2	Prostate Cancer With Peritoneal Carcinomatosis: A Robotic-assisted Radical Prostatectomy-based Case Series. <i>Urology</i> , 2022, 167, 171-178.	1.0	4
3	Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 334.	3.7	44
4	Differential treatment outcomes in <i>BRCA1/2</i> , <i>CDK12</i> , and <i>ATM</i> mutated metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2021, 127, 1965-1973.	4.1	15
5	Abstract 547: Urine tumor DNA MRD detection and correlation with pathologic complete response in muscle-invasive bladder cancer treated with curative-intent radical cystectomy. , 2021, , .		0
6	Primary Prostatic Synovial Sarcoma With Pulmonary Metastases Identified by Routine Next-Generation Sequencing. <i>JCO Precision Oncology</i> , 2021, 5, 1133-1140.	3.0	0
7	Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003732.	8.4	38
8	Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS). <i>Journal of Urology</i> , 2021, 206, 613-622.	0.4	18
9	Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 757-774.	3.8	16
10	423...A phase 2 study of ibrutinib as neoadjuvant therapy in patients with localized prostate cancer. , 2021, 9, A453-A453.		3
11	Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. <i>European Urology</i> , 2020, 77, 333-341.	1.9	65
12	Review: Brain Metastases in Bladder Cancer. <i>Bladder Cancer</i> , 2020, 6, 237-248.	0.4	4
13	Elective Cytoreductive Nephrectomy After Checkpoint Inhibitor Immunotherapy in Patients With Initially Unresectable Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 361-366.	1.9	13
14	Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization. <i>Current Urology Reports</i> , 2019, 20, 64.	2.2	21
15	Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 2019, 37, 323-330.	2.6	2
16	Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. <i>Cell</i> , 2018, 173, 1770-1782.e14.	28.9	400
17	Hospice Utilization and Its Effect on Acute Care Needs at the End of Life in Medicare Beneficiaries With Hepatocellular Carcinoma. <i>Journal of Oncology Practice</i> , 2017, 13, e197-e206.	2.5	35
18	Reply to C.D. Woodrell et al. <i>Journal of Oncology Practice</i> , 2017, 13, 406-406.	2.5	0

#	ARTICLE	IF	CITATIONS
19	Diagnosis of Concurrent Pulmonary Tuberculosis and Tuberculous Otitis Media Confirmed by Xpert MTB/RIF in the United States. <i>Infectious Diseases in Clinical Practice</i> , 2016, 24, 180-182.	0.3	6
20	NOD2 status and human ileal gene expression. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1649-1657.	1.9	28